Cara Therapeutics Inc (CARA)
0.7782
+0.01
(+0.78%)
USD |
NASDAQ |
May 03, 16:00
0.7787
0.00 (0.00%)
After-Hours: 20:00
Cara Therapeutics Research and Development Expense (Quarterly): 28.42M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 28.42M |
| September 30, 2023 | 25.45M |
| June 30, 2023 | 30.31M |
| March 31, 2023 | 24.33M |
| December 31, 2022 | 26.01M |
| September 30, 2022 | 24.69M |
| June 30, 2022 | 19.90M |
| March 31, 2022 | 21.27M |
| December 31, 2021 | 22.83M |
| September 30, 2021 | 15.51M |
| June 30, 2021 | 25.22M |
| March 31, 2021 | 19.13M |
| December 31, 2020 | 27.14M |
| September 30, 2020 | 21.07M |
| June 30, 2020 | 26.11M |
| March 31, 2020 | 33.54M |
| December 31, 2019 | 29.86M |
| September 30, 2019 | 35.99M |
| June 30, 2019 | 24.36M |
| March 31, 2019 | 23.61M |
| December 31, 2018 | 22.80M |
| September 30, 2018 | 22.30M |
| June 30, 2018 | 17.00M |
| Date | Value |
|---|---|
| March 31, 2018 | 13.43M |
| December 31, 2017 | 11.58M |
| September 30, 2017 | 9.151M |
| June 30, 2017 | 6.961M |
| March 31, 2017 | 20.84M |
| December 31, 2016 | 20.28M |
| September 30, 2016 | 9.671M |
| June 30, 2016 | 10.76M |
| March 31, 2016 | 8.546M |
| December 31, 2015 | 7.568M |
| September 30, 2015 | 5.584M |
| June 30, 2015 | 4.684M |
| March 31, 2015 | 3.385M |
| December 31, 2014 | 3.459M |
| September 30, 2014 | 6.208M |
| June 30, 2014 | 3.20M |
| March 31, 2014 | 2.201M |
| December 31, 2013 | 1.978M |
| September 30, 2013 | 3.764M |
| June 30, 2013 | 2.021M |
| March 31, 2013 | 0.922M |
| December 31, 2012 | 1.023M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
15.51M
Minimum
Sep 2021
35.99M
Maximum
Sep 2019
25.32M
Average
25.22M
Median
Jun 2021
Research and Development Expense (Quarterly) Benchmarks
| Nektar Therapeutics | 29.94M |
| Stereotaxis Inc | 2.212M |
| Cerus Corp | 14.29M |
| Avid Bioservices Inc | -- |
| Rigel Pharmaceuticals Inc | 3.186M |